Please assess the completion status of the following clinical trial:

Trial Title: Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent obtained before starting any study-specific procedure.~2. Symptomatic elderly MM newly diagnosed by EBMT criteria older than 65 years.~3. Performance status (ECOG) ≤ 2.~4. Have pre-treatment clinical laboratory values meeting the following criteria within 14 days of randomization:~   * platelet count ≥ 75x109/L~  * haemoglobin ≥ 8g/dL~  * absolute neutrophil count (ANC) ≥ 1.0x109/L~  * Serum bilirubin ≤ 1.5 mg/dL and alkaline phosphatise ≤ 2.5 x ULN AST, ALT ≤ 2.5 x ULN~  * Serum creatinine ≤2,5 mg/dl~Exclusion Criteria:~1. Patient previously received treatment with Velcade or Revlimid.~2. Patient previously received treatment for Multiple Myeloma.~3. Patient has ≥ Grade 2 peripheral neuropathy within 14 days before enrolment.~4. Patient has hypersensitivity to bortezomib, boron, mannitol or lenalidomide.~5. Patient has received other investigational drugs with 28 days before enrolment.~6. Patient had a myocardial infarction within 6 months of enrolment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.~7. Patient currently is enrolled in another clinical research study and/or is receiving an investigational agent for any reason.~8. Radiation therapy within 30 days before randomization, at least patient has had antialgic radiation. Radiation therapy will be afterwards permitted during the treatment period if it is indicated due to the presence of plasmacytomas

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MPV followed by Revlimid/Low Dose Dexamethasone (Rd) (Type: ACTIVE_COMPARATOR): Melphalan/Prednisone/Velcade (MPV) followed by Revlimid/Low Dose Dexamethasone (Rd)
- Alternating MPV with Revlimid/Low Dose Dexamethasone (Type: EXPERIMENTAL): Alternating Velcade/Melphalan/Prednisone (MPV) with Revlimid/Low Dose Dexamethasone (Rd)

Based on this trial design, predict the completion outcome and termination type (if applicable).